Abstract
Drugs for inflammatory intestinal disease are generally regarded as non-teratogenic but an association between the use of 5-aminosalicylic acid drugs and congenital malformations, notably congenital heart defects, seems to exist. It appears to be linked to underlying ulcerative colitis and may be an example of confounding by indication. Use of drugs in early pregnancy may be an indicator of a flare of the underlying disease which may cause a disturbed heart morphogenesis. Further information is needed based on large but detailed materials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medication. Gastroenterology. 2014;146:76–84.
Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22:542–9.
Boyd HA, Basit S, Harpsøe MC, Wohlfart J, Jess T. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One. 2015;10:e0129567. https://doi.org/10.1371/journal.pone.0129567.
Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114:23–8.
Dominitz JA, Young JCC, Boyko EJ. Outcomes on infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002;97:641–8.
Källén B. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. Scand J Gastroenterol. 2014;44:442–8.
Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998;12:1101–8.
Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981;80:72–6.
Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99:656–61.
Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52:243–7.
Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406–13.
Rahimi R, Nikfar S, Rezale A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–5. https://doi.org/10.1016/j.reprotox2007.11.010.
Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21:489–74.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Källén, B. (2019). Maternal Use of Drugs for Inflammatory Intestinal Disease and Infant Congenital Malformations. In: Maternal Drug Use and Infant Congenital Malformations. Springer, Cham. https://doi.org/10.1007/978-3-030-17898-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-17898-7_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17897-0
Online ISBN: 978-3-030-17898-7
eBook Packages: MedicineMedicine (R0)